Study identifier:D7917C00223
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex)-Placebo Combination to the Anastrozole –ZD1839 (Iressa) Combination as Neoadjuvant Treatment in Postmenopausal Women with Stage I-IIIB (tumour =2cm) Non Inflammatory Breast Cancer and Oestrogen Receptor (ER) and /or Progesterone Receptor (PgR) Positive Tumours)
Breast Cancer
N/A
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|